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Abstract
Background To assess the time interval to recurrent
choroidal neovascular membrane (CNV) activity in eyes
with neovascular age-related macular degeneration (AMD)
after intravitreal anti-VEGF therapy.
Methods Data from all patients who received intravitreal
ranibizumab injections for neovascular AMD at the
University of Cologne prior to February 2009 were
retrospectively reviewed. Patients were treated on a pro re
nata (PRN) basis and eyes with active CNV received three
consecutive monthly injections. Recurrence of CNV activity
was defined as recurrence of intra- or subretinal fluid on
optical coherence tomography (OCT) or leakage on fluores-
cein angiography (FA) after initial resolution of fluid and
leakage following anti-VEGF therapy. All eyes showing at
least two documented recurrences of CNV activity during
follow-up were included in this analysis. Recurrence intervals
werecalculatedand weredeemedtoberegular orperiodicalif
the difference between recurrence interval times was less than
50 days.
Results Twenty-nine eyes of 28 patients met the inclusion
criteria. Two to six recurrences were detected per case
(mean 2.8 ± 1.1 recurrences). Recurrence intervals ranged
from 41 days to 523 days (mean 5.5±3.4 months, median
4.5 months). Twenty-two eyes (76%) showed at least two
periodical recurrence intervals. In 12 eyes (41%), all
recurrences occurred at regular intervals (2-4 recurrences,
mean 2.3 ± 0.6 recurrences). Seven eyes (24%) showed
irregular recurrence intervals (2-3 recurrences, mean 2.1 ± 0.4
recurrences). All 11 eyes with a classic CNV lesion
component showed at least two periodical recurrence
intervals. Eyes with occult CNV lesions showed periodical
recurrence intervals in 11 out of 18 cases (61%).
Conclusions Preliminary data indicate that periodical
recurrences of CNV activity may be seen in eyes with
neovascular AMD undergoing anti-VEGF therapy.
Knowledge of individual recurrence interval times may
allow for the development of an individualized treatment
plan and prophylactic therapy.
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Introduction
Neovascular age-related macular degeneration (AMD) is a
leading cause of severe and irreversible vision loss in the
developed world among people 50 years of age or older
[1–5]. Treatment of neovascular AMD with monthly
injections of ranibizumab (Lucentis, Genentech Inc, South
San Francisco, CA, USA), an antibody fragment that
avidly binds to vascular endothelial growth factor
(VEGF), is the standard treatment of care for neovascular
AMD [6, 7]. The phase III pivotal clinical trials,
Minimally Classic/Occult Trial of the Anti-VEGF Anti-
body Ranibizumab in the Treatment of Neovascular AMD
(MARINA) [7] and Anti-VEGF Antibody for the Treat-
ment of Predominantly Classic Choroidal Neovasculariza-
tion (CNV) in AMD (ANCHOR) [6], have demonstrated
R. Hörster: T. Ristau: S. Liakopoulos (*)
Department of Vitreoretinal Surgery, Center for Ophthalmology,
University of Cologne,
Kerpener Strasse 62,
50924 Cologne, Germany
e-mail: sandra.liakopoulos@uk-koeln.de
S. R. Sadda
Doheny Retina Institute, Doheny Eye Institute, Keck School of
Medicine of the University of Southern California,
Los Angeles, CA, USA
Graefes Arch Clin Exp Ophthalmol (2011) 249:645–652
DOI 10.1007/s00417-010-1588-2the efficacy and safety of monthly ranibizumab injections
for the preservation and improvement of visual acuity by
using a fixed-dosing regimen requiring a 0.5-mg or 0.3-mg
injection of ranibizumab every month for 2 years [6, 7].
In the PIER Study [8], patients were given three
injections of ranibizumab at monthly intervals followed
by injections at a quarterly interval, for a total of six
scheduled injections over a 1-year period. Patients showed
an early gain in visual acuity after the first three injections,
but thereafter had a mean visual acuity decline. Apparently
better results were obtained using an optical coherence
tomography (OCT) guided, variable dosing regimen
(PrONTO study) [9, 10]. In this small, uncontrolled study,
patients were given three consecutive monthly injections of
ranibizumab, and were then reassessed monthly. Reinjec-
tion was performed if specific pre-defined criteria for
recurrent or persistent activity were present, including fluid
accumulation on OCT or leakage on fluorescein angiogra-
phy. Though the PrONTO data is not directly comparable to
the phase III trials, PrONTO functional outcomes appeared
superior to quarterly injections, though perhaps not as good
as with monthly injections. Another prospective study
analyzing the outcome after pro re nata (PRN) treatment
with bevacizumab (Bashshur) [11, 12], as well as a
controlled, prospective phase III study using ranibizumab
therapy as needed, the SUSTAIN study, demonstrated
similar results [13].
Although the as-needed dosing strategy (PRN treatment)
may reduce the number of intravitreal injections and allow
the treatment plan to be individualized, it may still require
monthly visits to specialized centers. In contrast to
mandated monthly injections, patients treated with PRN
strategies may develop multiple recurrences of CNV
activity over time. Recurrent intra- or subretinal fluid could
potentially induce progressive, cumulative dysfunction of the
neural retina, resulting in a decreased ability of the retina to
recover despite further treatment.
The “treat-and-extend approach” aims to individualize
the treatment plan and decrease the number of injections
per year, but at the same time attempts to achieve a fluid-
free macula and decrease the number of visits [14–17].
Patients treated with the treat-and-extend regimen typically
receive monthly injections until the signs of exudation have
resolved. The treatment interval is then sequentially
lengthened by 1 to 2 weeks as long as there are no signs
of recurrent exudation on OCT or fluorescein angiography
(FA). When recurrent exudation is detected on a follow-up
visit, the treatment interval is reduced to the prior interval.
Treatment is rendered at every visit but the time between
visits is individualized based on a given patient’s response
to treatment.
Another individualized treatment strategy that aims to
avoid recurrent CNV activity as well as additionally to
further reduce the number of injections and visits may be
to perform the injection immediately prior to the next
recurrence. This would require the ability to determine
or predict the recurrence interval for an individual
patient. In this study, we analyzed the recurrence
intervals of patients undergoing anti-VEGF therapy for
neovascular AMD to determine whether predictable,
regular recurrence patterns were present for individual
patients.
Methods
Data from all patients who began intravitreal ranibizumab
therapy for neovascular AMD at the University of
Cologne prior to February 2009 were retrospectively
reviewed. To be included in this study, eyes were
required to demonstrate at least two instances of
recurrent CNV activity during follow-up. Recurrent
activity was defined as the re-appearance of fluid on
OCT (in the intraretinal or subretinal compartments) and/
or leakage on angiography following a previous fluid-free
and/or leakage-free interval. Eyes with persistent fluid
requiring continuous injections, eyes with sustained resolu-
tionoffluidwithouttworecurrences,andeyesofpatientswho
didnotreturnfor follow-upwereexcluded.Eyesthatreceived
photodynamic therapy or vitreous surgery during follow-up
werealsoexcludedfromthisanalysis.Best-correctedbaseline
visualacuity(Snellen),ageofthepatient,CNVlesionsubtype
and dates of intravitreal injections were collected. For every
visit, OCT and FA images were reviewed to determine
whether signs of CNV activity were present. Approval
for data collection and analysis was obtained from the
institutional review board of the University of Cologne.
The research adhered to the tenets set forth in the
Declaration of Helsinki.
In general, patients received three consecutive monthly
injections of ranibizumab and were re-treated on a PRN
basis. Bevacizumab was used instead of ranibizumab
intermittently, if the confirmation for the assumption of
costs was delayed by the insurance company. FA was
performed in all cases prior to the first injection. At follow-
up visits, FA and/or OCT imaging was performed. Stratus
OCT (Carl Zeiss Meditec, Dublin, CA) was used until June
2008, since then a high-resolution Spectral domain OCT
(Spectralis HRA + OCT, Heidelberg Engineering GmbH,
Dossenheim, Germany) was available. Since 2009, FAwas
performed at follow-up visits only if CNV activity was
questionable based on OCT images, however, at least once
a year. Eyes with intra- or subretinal fluid accumulation on
OCT or leakage on FA at subsequent follow-up examina-
tions were re-treated with 3 consecutive monthly injections
of ranibizumab. If no CNVactivity was detected at follow-
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noticed a decrease in visual acuity or perception of new
metamorphopsia, or were scheduled for follow-up after
4-6 weeks.
Recurrence intervals were calculated between the date
of the last intravitreal injection and the follow-up visit on
which recurrent CNV activity was diagnosed. For cases in
which the difference between recurrence interval times
was less than 50 days, the recurrences were deemed to
occur at regular intervals, or termed “periodical.” If the
recurrence interval times differed by more than 50 days,
they were termed irregular. The broad 50-day window was
chosen as some patients did not return at monthly
intervals, and only returned at the first sign of visual
decrease or new visual symptoms. Thus, some patients
may have had recurrent fluid that preceded their re-
assessment in the clinic.
Statistical analysis was performed using commercially
available software (SigmaPlot 2008 for Windows, version
11.0, SYSTAT Software Inc., Erkrath, Germany). Baseline
characteristics were compared between eyes with and
without periodical CNV activity using the t test or Mann–
Whitney rank-sum test, depending on whether the data
matched the pattern expected in a population with a normal
distribution. The Mann-Whitney rank-sum test was also
used to compare the recurrence interval times between
different CNV lesion types and different anti-VEGF agents.
The correlation between CNV lesion subtypes and period-
ical activity was calculated using Fisher's exact test. The
correlation between mean interval duration and baseline
visual acuity or age of the patient was calculated using
Pearson correlation. p values <0.05 were considered
statistically significant.
Results
A total of 646 eyes began ranibizumab therapy for neo-
vascular AMD prior to February 2009 at the University of
Cologne. Out of those cases, 390 eyes received fewer than six
anti-VEGF injections prior to February 2010, either because
no additional injections were required or because they were
lostto follow-up atour clinic. Out of the remaining 256 cases,
29 eyes of 28 patients showed two or more documented
recurrences of CNV activity during follow-up and were
eligible for analysis. In 11 out of those cases (38%),
bevacizumab was used instead of ranibizumab intermittently.
There was no statistically significant difference between
recurrence interval times that were calculated following
bevacizumab injections and ranibizumab injections.
Ten patients were male (36%) and 18 patients female
(64%). Mean age was 75±7 years (range 62 to 89). Visual
acuityatbaseline was0.5±0.3logMAR(20/60±3lines,range
20/25 to 20/400). Nine cases showed predominantly classic
CNV, two cases minimally classic CNV, and 18 eyes occult
with no classic CNV. Additionally, retinal angiomatous
proliferation(RAP)waspresentinsevencases,andpolypoidal
choroidal vasculopathy (PCV) was detected in two cases.
The mean follow-up time was 28.8±9.2 months (range
from 12 to 42 months). The total number of injections
during follow-up ranged from 6 to 19 injections (mean
number of injections per year of 4.9±1.8). Two to 6
recurrences of CNV activity were detected per case (mean
2.8±1.1 recurrences). Recurrence intervals ranged from
41 days to 17 months (mean 5.5±3.4 months, median
4.5 months) (Fig. 1). There was no significant correlation
between the mean or median recurrence interval time and
baseline visual acuity or age of the patient.
Fig. 1 Recurrence intervals
(months) for all cases. One case
showed six recurrences (red),
two cases five recurrences
(green), three cases four
recurrences (blue), seven cases
three recurrences (yellow) and
16 cases two recurrences (black
and white) during follow-up
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periodical activity of at least two recurrence intervals, with
12 eyes (41% out of 29) showing periodical activity of all
recurrence intervals (number of recurrences in this group
ranged from 2 to 4, mean 2.3 ± 0.6 recurrences). Seven
eyes (24%) showed irregular recurrences (range 2–3
recurrences, mean 2.1 ± 0.4 recurrences). A summary of
all data is provided in Table 1.
There was a statistically significant difference (p<0.05)
regarding baseline visual acuity between eyes with no
periodical recurrence intervals (mean 20/40±2 lines) and
eyes with at least two periodical recurrence intervals (mean
20/80±3 lines). However, there was no statistically signif-
icant difference between the two groups regarding the age
of the patient or the mean or median recurrence interval
times. For example, one eye developed two regular CNV
recurrences 5 months after the last injection that was
required to resolve all intra- or subretinal fluid, whereas
two eyes showed CNV recurrences after 11 and 12 months.
One patient presented with four recurrences of CNV
activity within a follow-up time of 16.5 months, all detected
2.3 to 3.6 months after the last injection. One patient
demonstrated six recurrences of CNV activity during a
follow-up of 41 months, all within the range of 1.8 to
6.6 months after the last injection. Four out of these six
recurrences were detected within the range of 1.8–
3.1 months and were considered regular. In one patient,
both eyes were eligible for analysis. Both eyes demonstrat-
ed occult CNV with RAP, one eye developed five
recurrences within a follow-up time of 40 months that
occurred 3.9, 4.0, 4.5, 5.6, and 5.7 months after the last
injection (Fig. 2). Three out of these five recurrences were
Table 1 Summary of data from all cases
Case no. Age at
baseline
Baseline BCVA
(Snellen)
CNV lesion
subtype
RAP Follow-up
(months)
Number of
recurrences
detected
Periodical
recurrence
intervals
Recurrence intervals times
(Months)
1 68 20/30 Occult CNV No 17.0 2 0 4.8; 1.3
2 77 20/50 Min. classic No 33.1 2 2 11.5; 11.1
3 86 20/80 Occult CNV No 30.5 2 0 7.4; 5.4
4 87 20/40 Occult CNV Yes 21.3 2 0 7.4; 4.2
5 81 20/25 Occult CNV Yes 27.7 2 2 5.6; 7.2
6 78 20/120 Pred. classic CNV No 18.3 2 2 3.6; 1.9
7 68 20/25 Occult CNV No 19.1 2 0 2.3; 4.5
8 63 20/50 Pred. classic CNV No 33.0 2 2 12.0; 11.0
9 70 20/200 Pred. classic CNV No 17.8 2 2 4.9; 5.1
10 74 20/40 Occult CNV, PCV No 25.0 2 0 7.0; 3.1
11 68 20/160 Occult CNV, PCV No 14.7 2 2 2.6; 3.8
12 80 20/50 Pred. classic CNV No 14.9 2 2 4.1; 4.9
13 77 20/60 Occult CNV Yes 37.6 2 0 16.0; 6.3
14 75 20/100 Pred. classic CNV No 33.2 2 2 13.3; 11.6
15 62 20/25 Occult CNV Yes 31.1 2 2 10.2; 11.0
16 82 20/120 Occult CNV No 12.1 2 2 4.2; 2.5
17 82 20/40 Pred. classic CNV No 35.5 3 2 3.5; 4.6; 5.5
18 70 20/50 Occult CNV No 33.1 3 2 4.0; 2.4; 1.8
19 76 20/25 Occult CNV No 29.8 3 0 13.3; 2.1; 4.0
20 71 20/40 Pred. classic CNV No 28.5 3 2 3.6; 5.5; 2.8
21 71 20/400 Occult CNV No 35.5 3 3 5.4; 5.5; 4.9
22 76 20/200 Pred. classic CNV No 38.6 3 2 7.5; 6.7; 13.9
23 77 20/100 Occult CNV Yes 37.6 3 2 17.1; 2.3; 2.7
24 79 20/30 Occult CNV No 34.9 4 3 6.6; 2.5; 4.0; 2.9
25
a 75 20/50 Occult CNV Yes 36.5 4 2 5.0; 10.3; 4.7; 1.9
26 77 20/40 Min. classic No 16.5 4 4 3.6; 2.3; 3.6; 2.4
27
a 74 20/100 Occult CNV Yes 39.8 5 3 4.5; 4.0; 5.6; 3.9; 5.7
28 89 20/50 Occult CNV No 42.7 5 4 3.8; 2.5; 3.7; 6.2; 3.3
29 76 20/200 Pred. classic CNV No 41.1 6 4 6.6; 3.1; 2.9; 4.8; 1.9; 1.8
aBoth eyes of one patient
Abbr.: CNV choroidal neovascularization, Min. minimal, Pred. predominantly, BCVA best-corrected visual acuity, RAP retinal angiomatous
proliferation, PCV polypoidal choroidal vasculopathy. For cases in which the difference between recurrence interval times was less than 50 days,
the recurrences were termed “periodical”
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intervals was 56 days. The fellow-eye presented four
recurrences within a follow-up of 37 months (recurrence
intervals 1.9, 4.7, 5.0, and 10.3 months, two out of those
four were considered periodical).
The CNV lesion type for each eye was defined using
FA at baseline. All eyes with classic CNV lesion
components (predominantly classic and minimally classic
CNV) showed at least two periodical recurrence intervals
(11 out of 11 cases), whereas eyes with purely occult
CNV lesions showed periodical recurrence intervals only
in 11 out of 18 cases (61%, including five out of seven
eyes with RAP) (p=0.026) (Fig. 3). However, there was
no statistically significant difference between CNV lesion
Fig. 2 Example showing a case with occult CNV and RAP
demonstrating five recurrences during a 3-year follow-up (the most
recent three out of those five are shown here). The recurrence interval
times ranged between 3.9 and 5.7 months. Visual acuity (VA)
decreased progressively over time. OCT Optical coherence tomogra-
phy, FA fluorescein angiography
Graefes Arch Clin Exp Ophthalmol (2011) 249:645–652 649types regarding the mean or median recurrence interval
time.
Discussion
Determining the optimal dosing schedule for anti-VEGF
therapy in neovascular AMD remains a challenge because
neither the effect of the drugs in human eyes nor the nature
of the disease itself is fully understood. The MARINA and
ANCHOR trials so far reported the best functional outcome
results by using monthly injections of ranibizumab [6, 7].
Monthly injections may be necessary in some patients in
order to achieve the best possible increase in visual acuity
and to preserve retinal function over time. However, many
patients may require fewer injections. PRN treatment
regimens as well as the treat and extend regimen aim to
decrease the number of injections per year. In our dataset,
eyes treated “as needed” received a mean number of 4.9±
1.8 injections per year. Prospective studies using a PRN
treatment regime also reported a lower injection rate per
year (PrONTO [9]: 5.6±2.3 injections per year, Bashshur
[11]: 3.4 injections per year). The PrONTO results showed
a great inter-patient variability in the number of injections
needed, ranging from 3 to 23 throughout a 2-year period
[10]. In addition, the PrONTO study was the first to show
that in certain specific cases, treatment by ranibizumab
could be stopped, at least temporarily, without any loss of
benefit. No statistically significant correlation was found
between the need for more frequent injections and visual
acuity outcomes in the PrONTO and in the Bashshur study
[9–12].
However, PRN treatment so far failed to demonstrate
functional outcomes comparable to the MARINA and
ANCHOR results. Additionally, patients treated less than
monthly may develop multiple recurrences of CNVactivity,
potentially resulting in progressive damage of the neuro-
sensory retina and compromising the long-term visual
outcome [15]. In the PrONTO study, 37 out of 40 eyes
(93%) developed recurrent fluid within the 12-month
follow-up period [9]. Dagostar et al. reported recurrences
of CNVactivity in 62 out of 131 eyes (47.3%) treated with
ranibizumab as needed with a follow-up of at least 6 months
(mean 12 months) in a retrospective study [18]. Our dataset
does not provide information regarding the incidence of
CNV recurrences, as we included only eyes with at least
two documented recurrences in our analysis. Despite
further treatment, recovery of visual acuity may be less
likely after frequent recurrence of fluid than in treatment
naive eyes.
The “treat-and-extend approach” aims to achieve a
fluid-free macula and decrease the number of visits using
an individualized treatment plan with intervals that are
sequentially lengthened until recurrent CNV activity is
detected [14–17]. Gupta et al. reported that in 45.7% of
eyes, no recurrent CNV activity was detected during a
m e a nf o l l o w - u pp e r i o do f1 . 5 2y e a r s[ 14]. However,
46.7% of eyes still showed between 1 and 4 recurrences
(the remaining 7.6% of eyes demonstrated persistent fluid
despite monthly treatment). Eyes treated with the treat-
and-extend regimen receive injections at every visit. Thus,
the reported mean number of 8.36 injections in the first
year and 7.45 injections in the second year was higher than
reported in studies using the PRN approach. Engelbert et al.
used the treat-and-extend approach for 11 eyes with retinal
angiomatous proliferation and reported a total of 21 recur-
rences during a cumulative observation period of 336 months
[17]. The mean number of injections was seven in the first
year, six in the second year, and seven in the third year.
It is desirable to find a dosing regimen that is maximally
effective at preserving or improving visual acuity while at
the same time is intended to avoid CNV recurrences as well
as to further decrease the number of visits and injections
when they are not needed. One possible approach that may
fulfill those conditions would be to determine the individual
time point of every CNV recurrence. Re-injections of
ranibizumab shortly prior to a recurrence may avoid
recurrent leakage and fluid accumulation, as well as further
growth of the CNV lesion size. Therefore, avoiding
recurrent CNV activity with prophylactic injections may
protect the neural retina from additional damage and
improve the long-term prognosis. However, this approach
requires the ability to determine individual recurrence
intervals. Our study aims to analyze recurrence intervals
detected using a PRN regimen, and to determine whether
periodical recurrences may exist.
In our dataset, 22 out of 29 eyes demonstrated at least
two recurrences of CNV activity during follow-up that
occurred within a similar time interval (± 50 days). Some
patients developed multiple regular recurrences, e.g., in one
case, four recurrences ranging between 2.3 and 3.6 months
Fig. 3 Frequency of periodical recurrence interval times in various
CNV lesion types
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ranged from 41 days to 17 months, the mean recurrence
interval time was 5.5±3.4 months, the median 4.5 months
(calculated between the last injection that was necessary to
resolve all intra- or subretinal fluid and the date the
recurrence was noted). There was no difference regarding
the mean or median recurrence interval time between eyes
with regular recurrence intervals and eyes with irregular
recurrence intervals, indicating that eyes that develop a
recurrence of CNV activity early after the injection, are not
more likely to show periodical recurrence intervals than
eyes that remain fluid-free for months. Some eyes showed
regular recurrences after 5 months, some after 11 or
12 months. No correlation could be observed between
baseline visual acuity or age of the patient, and recurrence
interval times. The PrONTO study reported a mean
injection-free interval time of 4.5±2.7 months, ranging
between 2 and 10 months [9, 10]. Gupta et al., using the
treat-and-extend approach reported a mean maximum period
of extension of 79.9 days. No information is provided in both
studies regarding inter- or intra-individual variability of
recurrence intervals.
Our dataset does not allow to determine whether the
differences in recurrence interval times represent differ-
ences between individuals (e.g., genetically determined) or
between eyes (e.g., due to various CNV lesion types or
duration of the disease), as there was only one case with
bilateral recurrences in our study. In this case, one eye
demonstrated five recurrences (detected after 3.9, 4.0, 4.5,
5.6, and 5.7 months), the fellow eye demonstrated four
recurrences (detected after 1.9, 4.7, 5.0, and 10.3 months).
Five out of these nine recurrences were considered
periodical (difference less than 50 days), seven out of these
nine recurrences of both eyes were detected between 119
and 175 days after the last injection (thus within a time
interval of 56 days).
Our study was not designed to determine whether CNV
lesion type influenced the risk to develop a recurrence of
CNV activity. However, out of those cases in which more
than two recurrences were detected, eyes with a classic
CNV lesion component appeared to be more likely to
manifest a regular recurrence interval than eyes with occult
CNV only. Because classic CNV is believed to correspond
to type II histologic CNV (i.e., in the subretinal space), it is
possible that patients whose eyes contained classic CNV
may be more sensitive to detecting early signs of recurrence
than patients with occult CNV (type I histologic CNV in the
sub-RPE space). Certainly, it is well established that classic
CNV lesions are often associated with a more rapid
decrease in vision, whereas occult CNV lesions may remain
indolent for prolonged periods of time [19]. We also
observed that eyes with at least two periodical recurrence
intervals presented with poorer baseline visual acuity than
eyes with irregular recurrences, but the explanation for this
phenomenon is uncertain.
Limitations of our study include the retrospective
collection of the data, as well as the small dataset. As we
did not monitor all patients monthly, one cannot exclude the
possibility that recurrences of CNV activity have been
detected somewhat later because patients did not perceive
the decrease in vision or delayed the examination. To
address this, differences in recurrence interval times up to
50 days were still considered regular. Only 29 cases were
eligible for analysis out of 646 eyes that received
ranibizumab therapy within the analyzed time period. This
may be explained by the fact that most cases only received
few injections in Cologne but were followed and re-injected
by outpatient doctors. Some patients may have been treated
until the intra- and subretinal fluid resolved and stayed dry
thereafter, some never showed complete absence of fluid,
and thus did by definition not suffer from a recurrence.
Furthermore, some patients may have suffered from a
severe decrease in vision due to exudative process and may
have been lost to follow-up.
Despite those limitations, we could demonstrate that
regular recurrences of CNV activity may occur in some
eyes with neovascular AMD, and the recurrence interval
time may vary between individuals. The reason for this is
not yet fully understood. A larger, prospective trial
would be required to evaluate whether individually
adjusted prophylactic injections of ranibizumab may
allow avoidance of CNV recurrences, while still reducing
the number of injections and visits per year and
ultimately improving the long-term outcome in patients
with neovascular AMD.
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